A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1613

Enrollment

NETWORK

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: bevacizumab
DRUG: docetaxel
DRUG: doxorubicin
DRUG: cyclophosphamide
DRUG: pegfilgrastim

Sponsor

NSABP Foundation Inc

Collaborators

[object Object]
[object Object]